Executive Summary: Generative AI startups are often valued on a blend of revenue quality, contract durability, technical defensibility, and unit economics rather than on revenue alone. For buyers and investors, the real question is not simply how fast a company is growing, but whether that growth is repeatable and profitable enough to justify a premium […]
Executive Summary. Valuing an artificial intelligence company requires more than applying a standard revenue multiple or discounted cash flow model. Investors and buyers look closely at recurring revenue quality, model differentiation, proprietary data access, infrastructure efficiency, and the cost of scaling compute as usage grows. For San Francisco business owners, especially those operating in venture-backed […]
Executive Summary. Electronic health record and health IT software companies are typically valued on a mix of recurring revenue quality, customer retention, implementation stickiness, and the difficulty patients and providers face when switching systems. For San Francisco business owners in this sector, the headline ARR figure matters, but it does not tell the full story. […]
Executive Summary: AI-powered diagnostics companies are valued on more than software revenue or patent portfolios. Buyers and investors typically assess FDA clearance, clinical validation, reimbursement pathways, licensing economics, recurring revenue quality, and how deeply the platform is embedded in provider workflows. For San Francisco business owners, especially those building in biotech, life sciences, and enterprise […]
Executive Summary: Revenue cycle management (RCM) software companies are often valued on more than current earnings. Buyers and investors assess how effectively the platform converts medical claims into cash, how much revenue it generates per provider, how often claims are successfully collected, and how much recurring revenue is retained over time. For RCM businesses, metrics […]
Executive summary: Valuing a telehealth platform requires more than looking at topline growth. Buyers and investors focus on patient visit volume, revenue per visit, payer contract penetration, retention, and how much of the pandemic-era demand has normalized. In practice, telehealth businesses are typically valued using a blend of revenue multiples, EBITDA multiples, and discounted cash […]
Executive Summary: Healthtech valuation is driven by a combination of recurring revenue quality, patient and provider engagement, clinical evidence, and regulatory readiness. For digital health companies, buyers and investors do not rely on revenue alone. They also examine ARR growth, retention, clinical outcomes, reimbursement potential, and the strength of FDA clearance or other regulatory milestones. […]
Executive Summary: InsurTech businesses are valued less like traditional insurance carriers and more like scaled, data driven technology platforms with underwriting exposure. For buyers and investors, the most important valuation drivers are loss ratio, combined ratio, premium growth, retention, and the quality of distribution. A strong InsurTech company can command premium valuation multiples when it […]
Executive Summary: Buy-now-pay-later, or BNPL, businesses are no longer valued primarily on growth momentum alone. For founders, investors, and acquirers, the most important valuation question is whether gross merchandise value (GMV), merchant fee rate, and default performance combine to produce durable unit economics. In a post-hype market, valuation depends less on headline volume and more […]
Neobank valuation is fundamentally different from the way traditional banks are priced. For investors, buyers, and founders, the key question is not simply how much capital a digital bank has raised or how fast its user base is growing, but whether those users are sticky, monetizable, and capable of producing a durable path to profitability. […]